Critères d'inclusion : - Histologic documentation of disease: B-cell NHL or CLL requiring therapy;
B-cell NHL: all participants must have relapsed or refractory disease. In addition, the following disease-specific criteria outlined below must be met
a) If diffuse large B-cell lymphoma (DLBCL): received, or not eligible for high-dose chemotherapy and autologous stem cell transplantation with curative intent,
b) If follicular lymphoma (FL)/ marginal zone lymphoma (MZL) (except mucosa-associated lymphoid tissue [MALT]), or Waldenstrom macroglobulinemia (WM): previously treated with at least 1 prior line of systemic therapy containing an anti-CD20 antibody,
c) If mantle cell lymphoma (MCL): previously treated with at least 1 prior line of systemic therapy containing an anti-CD20 antibody.
CLL or small lymphocytic lymphoma (SLL): relapsed or refractory with at least 1 prior line of systemic therapy containing a bruton tyrosine kinase inhibitor (BTKi)
and for Part B: participants must have measurable disease as defined by the appropriate disease response criteria.
- Eastern Cooperative Oncology Group (ECOG) performance status Grade of 0 or 1
- Cardiac parameters within the following range: corrected QT interval (QTc intervals corrected using Fridericia's formula [QTcF]) less than or equal to (<=) 480 milliseconds (ms) based on the average of triplicate assessments performed no more than 5 plus minus (+ - 3) minutes apart
- Women of childbearing potential must have a negative highly sensitive serum (Beta human chorionic gonadotropin) at screening and prior to the first dose of study drug
- Women must be:
a) not of childbearing potential,
b) of childbearing potential and practicing a highly effective, preferably user independent method of contraception (failure rate of less than (<) 1 percent (%) per year when used consistently and correctly) and agrees to remain on a highly effective method while receiving study drug and until 90 days after last dose
Critères de non-inclusion : - Known active central nervous system (CNS) involvement with lymphoma
- Prior solid-organ transplantation
- Either of the following:
a) received an autologous stem cell transplant <=3 months before the first dose of JNJ 75348780,
b) prior treatment with allogenic stem cell transplant <= 6 months before the first dose of JNJ-75348780, has evidence of graft versus host disease, or requires immunosuppressant therapy
- Prior chemotherapy, targeted therapy, immunotherapy, radiotherapy (with the exclusion of palliative radiation to limited sites that do not interfere with response assessment based on a sufficient number of other sites), or treatment with an investigational anticancer agent or an investigational drug (including investigational vaccines) within 2 weeks before the first administration of study drug. For investigational agents where the half-life is known, there should be a treatment-free window of at least 2 weeks or 5 half-lives
- Active autoimmune disease that requires systemic immunosuppressive medications (example, chronic corticosteroid, methotrexate, or tacrolimus)